{"title":"Kuntai capsule for the treatment of ovulatory disorder infertility: A systematic review and meta-analysis of randomized controlled trials","authors":"Xudong Zhang , Xue Bai , Lina Zhang , Ling Xiong , Juwen Zhang , Yun Li , Wenjing Chang , Wei Chen","doi":"10.1016/j.eujim.2024.102350","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Ovulatory disorders contribute significantly to infertility, due to menstrual cycle disturbances and endocrine abnormalities. Kuntai capsule, a Chinese patent medicine, has been widely used in China to enhance ovarian function and fertility<strong>.</strong> This review is to evaluate Kuntai capsule's potential benefits and harms for ovulatory disorder infertility (ODI).</p></div><div><h3>Methods</h3><p>Databases including China National Knowledge Infrastructure, WANFANG Database, Chinese Science and Technology Journal Database, Chinese Biomedical Literature Database, PubMed, Cochrane Library, and Embase were searched from their inception to May 2023. All Randomized Controlled Trials (RCTs) comparing the combination of Kuntai capsule with reproductive medicine to reproductive medicine for ODI were included. Primary outcomes were ovulation rate and pregnancy rate. Secondary outcomes were the number of mature ovarian follicles and adverse events.</p></div><div><h3>Results</h3><p>Meta-analysis was conducted on 27 RCTs with a total of 2506 patients. The results showed that the combination of Kuntai capsule with clomiphene citrate (CC) had better effect in ovulation rate (Risk Ratio (RR)=1.27, 95 % confidence interval (CI) [1.15, 1.40]) and pregnancy rate (RR=1.66, 95 % CI [1.37, 2.01]) in ODI patients. The combination of Kuntai capsule with letrozole (LE) demonstrated improvements in ovulation rate (RR=1.22, 95 % CI [1.15, 1.29]) and pregnancy rate (RR=1.57, 95 % CI [1.39, 1.77]) in ODI patients. However, further large-scale RCTs are needed to validate these findings.</p></div><div><h3>Conclusion</h3><p>The combination of Kuntai capsule with reproductive medicine may improve the ovulation rate, pregnancy rate, and number of mature ovarian follicles in patients with ODI. However, considering the methodological quality issues in the included studies, it may potentially affect the reliability of the conclusions to some extent.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"67 ","pages":"Article 102350"},"PeriodicalIF":1.9000,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876382024000209/pdfft?md5=7e25ac5f13ab9f66a31693a9a8cd46cf&pid=1-s2.0-S1876382024000209-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Integrative Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1876382024000209","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Ovulatory disorders contribute significantly to infertility, due to menstrual cycle disturbances and endocrine abnormalities. Kuntai capsule, a Chinese patent medicine, has been widely used in China to enhance ovarian function and fertility. This review is to evaluate Kuntai capsule's potential benefits and harms for ovulatory disorder infertility (ODI).
Methods
Databases including China National Knowledge Infrastructure, WANFANG Database, Chinese Science and Technology Journal Database, Chinese Biomedical Literature Database, PubMed, Cochrane Library, and Embase were searched from their inception to May 2023. All Randomized Controlled Trials (RCTs) comparing the combination of Kuntai capsule with reproductive medicine to reproductive medicine for ODI were included. Primary outcomes were ovulation rate and pregnancy rate. Secondary outcomes were the number of mature ovarian follicles and adverse events.
Results
Meta-analysis was conducted on 27 RCTs with a total of 2506 patients. The results showed that the combination of Kuntai capsule with clomiphene citrate (CC) had better effect in ovulation rate (Risk Ratio (RR)=1.27, 95 % confidence interval (CI) [1.15, 1.40]) and pregnancy rate (RR=1.66, 95 % CI [1.37, 2.01]) in ODI patients. The combination of Kuntai capsule with letrozole (LE) demonstrated improvements in ovulation rate (RR=1.22, 95 % CI [1.15, 1.29]) and pregnancy rate (RR=1.57, 95 % CI [1.39, 1.77]) in ODI patients. However, further large-scale RCTs are needed to validate these findings.
Conclusion
The combination of Kuntai capsule with reproductive medicine may improve the ovulation rate, pregnancy rate, and number of mature ovarian follicles in patients with ODI. However, considering the methodological quality issues in the included studies, it may potentially affect the reliability of the conclusions to some extent.
导言：由于月经周期紊乱和内分泌异常，排卵障碍是导致不孕不育的重要原因。昆泰胶囊是一种中成药，在中国被广泛用于提高卵巢功能和生育能力。方法检索中国知网、万方数据库、中文科技期刊数据库、中国生物医学文献数据库、PubMed、Cochrane Library和Embase等数据库，检索时间从开始至2023年5月。纳入了所有比较昆泰胶囊与生殖药物联合治疗 ODI 和生殖药物治疗 ODI 的随机对照试验（RCT）。主要结果为排卵率和妊娠率。结果对27项RCT共2506名患者进行了Meta分析。结果显示，坤泰胶囊与枸橼酸氯米芬（CC）联合用药对 ODI 患者的排卵率（风险比（RR）=1.27，95% 置信区间（CI）[1.15, 1.40]）和妊娠率（RR=1.66，95% CI [1.37, 2.01]）有更好的效果。坤泰胶囊与来曲唑（LE）的联合治疗显示，ODI 患者的排卵率（RR=1.22，95 % CI [1.15，1.29]）和妊娠率（RR=1.57，95 % CI [1.39，1.77]）均有所改善。结论坤泰胶囊与生殖医学联合应用可提高 ODI 患者的排卵率、妊娠率和成熟卵泡数。然而，考虑到纳入研究的方法学质量问题，可能会在一定程度上影响结论的可靠性。
期刊介绍：
The European Journal of Integrative Medicine (EuJIM) considers manuscripts from a wide range of complementary and integrative health care disciplines, with a particular focus on whole systems approaches, public health, self management and traditional medical systems. The journal strives to connect conventional medicine and evidence based complementary medicine. We encourage submissions reporting research with relevance for integrative clinical practice and interprofessional education.
EuJIM aims to be of interest to both conventional and integrative audiences, including healthcare practitioners, researchers, health care organisations, educationalists, and all those who seek objective and critical information on integrative medicine. To achieve this aim EuJIM provides an innovative international and interdisciplinary platform linking researchers and clinicians.
The journal focuses primarily on original research articles including systematic reviews, randomized controlled trials, other clinical studies, qualitative, observational and epidemiological studies. In addition we welcome short reviews, opinion articles and contributions relating to health services and policy, health economics and psychology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
